Sfoglia per Rivista
ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT
2015-01-01 Iovino, L; Caracciolo, F.; Orciuolo, E.; Buda, G.; Mazziotta, F.; Rousseau, M.; Galimberti, S.; Benedetti, E.; Petrini, M.
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
2008-01-01 Patriarca, F; Bacigalupo, A; Sperotto, A; Isola, M; Soldano, F; Bruno, B; van Lint, Mt; Iori, Ap; Santarone, S; Porretto, F; Pioltelli, P; Visani, G; Iacopino, P; Fanin, R; Bosi, A; Gitmo, ; Milone, G; Mauro, M; La Nasa, G; Dessalvi, P; Bonifazi, F; Servida, P; Lambertenghi, G; Corradini, P; Falda, M; Mazza, P; Benedetti, F; Raimondi, R; Selleri, C; Locasciulli, A; Alessandrino, P; Narni, F; Papineschi, Federico
Alterazioni cromosomiche e sister chromatid exchanges (SCE)in pazienti pediatrici affetti da Leucemia Linfoblastica Acuta (LLA)
1986-01-01 Simi, P; Sessa, Mr; Favre, C; Nardi, M; Consolini, Rita
Altered Expression of Jak-Stat Pathway as Possible Predictive Marker in Patients Affected by Chronic Myeloid Leukemia Receiving Tyrosin Kinase Inhibitors (TKIS)
2018-01-01 Grassi, S; Palumbo, S; Mariotti, V; Ciabatti, E; Guerrini, F; Perutelli, F; Barate, C; Petrini, M; Pellegrini, S; Galimberti, S
Association between Non-Hodgkin’s Lymphoma and essential thrombocythemia
1997-01-01 Carulli, Giovanni; Testi, C; Azzara', Antonio
ATHEROTHROMBOTIC RISK ASSESSMENT DURING TYROSINE KINASE INHIBITORS TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS: NEW INSIGHT?
2014-01-01 Bocchia, M; Galimberti, Sara; Aprile, L; Gozzini, A; Santilli, F; Sicuranza, A; Abruzzese, E; Defina, M; Barate, C; Scappini, B.
AUTOIMMUNE DISEASES AND MYELOID HEMATOLOGICAL DISORDERS: A POSSIBLE PATHOGENETIC RELATIONSHIP
2020-01-01 Galimberti, S.; Baratè, C.; Ricci, F.; Balducci, S.; Governato, G.; Fulvio, G.; Elefante, E.; Ferro, F.; Di Paolo, A.; Baglietto, L.; Petrini, M.; Baldini, C.
Autologous transplantation with Philadelphia chromosome negative stem cells mobilized in first chronic phase-chronic myeloid leukaemia
1999-01-01 Papineschi, Federico; Caracciolo, F; Benedetti, E; Galimberti, Sara; Favre, C; Greco, F; Capochiani, E; Carulli, Giovanni; Azzara', Antonio; Cecconi, N; Testi, R; Petrini, Mario
BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) COMBINATION FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PHASE II STAUDY.
2012-01-01 Offidani, M; Corvatta, L; Caraffa, P; Liberati, Am; Alesiani, F; Brunori, M; Caravita di Toritto, T; Gentili, S; Attolico, I; Mele, A; Pulini, S; Ballanti, S; Galimberti, Sara; Gozzetti, A; Coppetelli, U; Ledda, A; Leoni, P.
BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) EXERT A SUBSTANTIAL ACTIVITY WITH A MANAGEABLE TOXICITY IN PATIENTS WITH RELAPSED-REFRACTORY MULTIPLE MYELOMA
2014-01-01 M., Offidani; L., Corvatta; L., Maracci; Am, Liberati; S., Ballanti; I., Attoli co; P., Caraffa; F., Alesiani; T., Caravita di Toritto; S., Gentili; P., Tosi; M., Brunori; D., Derudas; A., Ledda; A., Gozzetti; C., Cellini; L., Malerba; A., Mele; S., Felici; Galimberti, Sara; P., Mondello; S., Pulini; U., Coppetelli; P., Fraticelli; P., Leoni
BK virus-associated cystitis in non-myeloablative and conventional transplant recipients with simultaneous cytomegalovirus reactivation successfully treated with cydofovir.
2001-01-01 Benedetti, E; Fazzi, R; Caracciolo, F; Galimberti, Sara; Vatteroni, Ml; Testi, R; Cecconi, N; Azzara', Antonio; Carulli, Giovanni; Cervetti, G; Papineschi, Federico
BORTEZOMIB (VEL) BASED REGIMENS IN MULTIPLE MYELOMA (MM) PATIENTS WITH RENAL IMPAIRMENT (RI): A PRELIMINARY RETROSPECTIVE ITALIAN MULTICENTER STUDY
2008-01-01 M., Gentile; 1 S., Ciolli; 2 M. T., Gentile M; Ciolli, S; Petrucci, Mt; Galimberti, Sara; Mele, G; Casulli, Af; Mannina, D; Piro, E; Morabito, F.
BORTEZOMIB COMBINED WITH HISTONE DEACETYLASE INHIBITOR ITF2357 OR ARSENIC TRIOXIDE EXERTS SYNERGISTIC ANTI-PROLIF- ERATIVE AND PRO-APOPTOTIC EFFECTS IN P39 CELL LINE: A POSSI- BLE NEW APPROACH TO HIGH-RISK MYELODYSPLASTIC SYNDROMES
2008-01-01 Galimberti, Sara; Canestraro, M; Savli, H; Palumbo, Ga; Nagy, B; Di Raimondo, F; Petrini, Mario
BORTEZOMIB IS ABLE TO INACTIVATE NF-KB AND DOWN-REGULATE WT1 GENE IN P39 CELL LINE: A POSSIBLE USE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES?
2008-01-01 Galimberti, Sara; Canestraro, M; Savli, H; Palumbo, Ga; Nagy, B; Di Raimondo, F; Petrini, Mario
c-Jun and GST-p expression in human plasma cells
1997-01-01 DI SIMONE, D; Galimberti, Sara; Mattii, Letizia; Petrini, Mario
Carboxy-Terminal Fragment of Osteogenic Growth Pepide In Vitro Increases Bone Marrow Cell Density In Idiopathic Myelofibrosis
2002-01-01 Fazzi, R; Pacini, S; Testi, R; Orciuolo, E; Testi, C; Azzara', Antonio; Carulli, Giovanni; Metelli, R; Petrini, Mario
Carboxy-terminal fragment of osteogenic growth peptide activity on essential thrombocytemia
2003-01-01 Fazzi, R; Galimberti, Sara; Pacini, S; Testi, R; Azzara', Antonio; Orciuolo, E; Trombi, L; Metelli, Mr; Petrini, Mario
CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUM- AB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE
2008-01-01 Galimberti, Sara; Cecconi, N; Cervetti, G; Buda, G; Orciuolo, E; Papineschi, Federico; Caracciolo, F; Benedetti, E; Petrini, Mario
Chronic Myeloid Leukemia with Extreme Thrombocytocis at the Diagnosis: a New Subset
2016-01-01 Sora, F.; Alessandra, I.; Latagliata, R; Castagnetti, F.; Fava, C.; Annunziata, M.; Gozzini, A.; Montefusco, E.; Avanzini, P.; Pregno, P.; Cerrano, M.; Celesti, F.; Galimberti, Sara; Bocchia, M.; Breccia, M.; Cattaneo, D.; Rosti, G; Sica, S.
Circulating ringed sideroblasts in the course of the initial erythremic phase of erythroleukemia
1996-01-01 Carulli, Giovanni; Fabiani, O; Azzara', Antonio
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT | 1-gen-2015 | Iovino, L; Caracciolo, F.; Orciuolo, E.; Buda, G.; Mazziotta, F.; Rousseau, M.; Galimberti, S.; Benedetti, E.; Petrini, M. | |
| Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) | 1-gen-2008 | Patriarca, F; Bacigalupo, A; Sperotto, A; Isola, M; Soldano, F; Bruno, B; van Lint, Mt; Iori, Ap; Santarone, S; Porretto, F; Pioltelli, P; Visani, G; Iacopino, P; Fanin, R; Bosi, A; Gitmo, ; Milone, G; Mauro, M; La Nasa, G; Dessalvi, P; Bonifazi, F; Servida, P; Lambertenghi, G; Corradini, P; Falda, M; Mazza, P; Benedetti, F; Raimondi, R; Selleri, C; Locasciulli, A; Alessandrino, P; Narni, F; Papineschi, Federico | |
| Alterazioni cromosomiche e sister chromatid exchanges (SCE)in pazienti pediatrici affetti da Leucemia Linfoblastica Acuta (LLA) | 1-gen-1986 | Simi, P; Sessa, Mr; Favre, C; Nardi, M; Consolini, Rita | |
| Altered Expression of Jak-Stat Pathway as Possible Predictive Marker in Patients Affected by Chronic Myeloid Leukemia Receiving Tyrosin Kinase Inhibitors (TKIS) | 1-gen-2018 | Grassi, S; Palumbo, S; Mariotti, V; Ciabatti, E; Guerrini, F; Perutelli, F; Barate, C; Petrini, M; Pellegrini, S; Galimberti, S | |
| Association between Non-Hodgkin’s Lymphoma and essential thrombocythemia | 1-gen-1997 | Carulli, Giovanni; Testi, C; Azzara', Antonio | |
| ATHEROTHROMBOTIC RISK ASSESSMENT DURING TYROSINE KINASE INHIBITORS TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS: NEW INSIGHT? | 1-gen-2014 | Bocchia, M; Galimberti, Sara; Aprile, L; Gozzini, A; Santilli, F; Sicuranza, A; Abruzzese, E; Defina, M; Barate, C; Scappini, B. | |
| AUTOIMMUNE DISEASES AND MYELOID HEMATOLOGICAL DISORDERS: A POSSIBLE PATHOGENETIC RELATIONSHIP | 1-gen-2020 | Galimberti, S.; Baratè, C.; Ricci, F.; Balducci, S.; Governato, G.; Fulvio, G.; Elefante, E.; Ferro, F.; Di Paolo, A.; Baglietto, L.; Petrini, M.; Baldini, C. | |
| Autologous transplantation with Philadelphia chromosome negative stem cells mobilized in first chronic phase-chronic myeloid leukaemia | 1-gen-1999 | Papineschi, Federico; Caracciolo, F; Benedetti, E; Galimberti, Sara; Favre, C; Greco, F; Capochiani, E; Carulli, Giovanni; Azzara', Antonio; Cecconi, N; Testi, R; Petrini, Mario | |
| BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) COMBINATION FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PHASE II STAUDY. | 1-gen-2012 | Offidani, M; Corvatta, L; Caraffa, P; Liberati, Am; Alesiani, F; Brunori, M; Caravita di Toritto, T; Gentili, S; Attolico, I; Mele, A; Pulini, S; Ballanti, S; Galimberti, Sara; Gozzetti, A; Coppetelli, U; Ledda, A; Leoni, P. | |
| BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) EXERT A SUBSTANTIAL ACTIVITY WITH A MANAGEABLE TOXICITY IN PATIENTS WITH RELAPSED-REFRACTORY MULTIPLE MYELOMA | 1-gen-2014 | M., Offidani; L., Corvatta; L., Maracci; Am, Liberati; S., Ballanti; I., Attoli co; P., Caraffa; F., Alesiani; T., Caravita di Toritto; S., Gentili; P., Tosi; M., Brunori; D., Derudas; A., Ledda; A., Gozzetti; C., Cellini; L., Malerba; A., Mele; S., Felici; Galimberti, Sara; P., Mondello; S., Pulini; U., Coppetelli; P., Fraticelli; P., Leoni | |
| BK virus-associated cystitis in non-myeloablative and conventional transplant recipients with simultaneous cytomegalovirus reactivation successfully treated with cydofovir. | 1-gen-2001 | Benedetti, E; Fazzi, R; Caracciolo, F; Galimberti, Sara; Vatteroni, Ml; Testi, R; Cecconi, N; Azzara', Antonio; Carulli, Giovanni; Cervetti, G; Papineschi, Federico | |
| BORTEZOMIB (VEL) BASED REGIMENS IN MULTIPLE MYELOMA (MM) PATIENTS WITH RENAL IMPAIRMENT (RI): A PRELIMINARY RETROSPECTIVE ITALIAN MULTICENTER STUDY | 1-gen-2008 | M., Gentile; 1 S., Ciolli; 2 M. T., Gentile M; Ciolli, S; Petrucci, Mt; Galimberti, Sara; Mele, G; Casulli, Af; Mannina, D; Piro, E; Morabito, F. | |
| BORTEZOMIB COMBINED WITH HISTONE DEACETYLASE INHIBITOR ITF2357 OR ARSENIC TRIOXIDE EXERTS SYNERGISTIC ANTI-PROLIF- ERATIVE AND PRO-APOPTOTIC EFFECTS IN P39 CELL LINE: A POSSI- BLE NEW APPROACH TO HIGH-RISK MYELODYSPLASTIC SYNDROMES | 1-gen-2008 | Galimberti, Sara; Canestraro, M; Savli, H; Palumbo, Ga; Nagy, B; Di Raimondo, F; Petrini, Mario | |
| BORTEZOMIB IS ABLE TO INACTIVATE NF-KB AND DOWN-REGULATE WT1 GENE IN P39 CELL LINE: A POSSIBLE USE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES? | 1-gen-2008 | Galimberti, Sara; Canestraro, M; Savli, H; Palumbo, Ga; Nagy, B; Di Raimondo, F; Petrini, Mario | |
| c-Jun and GST-p expression in human plasma cells | 1-gen-1997 | DI SIMONE, D; Galimberti, Sara; Mattii, Letizia; Petrini, Mario | |
| Carboxy-Terminal Fragment of Osteogenic Growth Pepide In Vitro Increases Bone Marrow Cell Density In Idiopathic Myelofibrosis | 1-gen-2002 | Fazzi, R; Pacini, S; Testi, R; Orciuolo, E; Testi, C; Azzara', Antonio; Carulli, Giovanni; Metelli, R; Petrini, Mario | |
| Carboxy-terminal fragment of osteogenic growth peptide activity on essential thrombocytemia | 1-gen-2003 | Fazzi, R; Galimberti, Sara; Pacini, S; Testi, R; Azzara', Antonio; Orciuolo, E; Trombi, L; Metelli, Mr; Petrini, Mario | |
| CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUM- AB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE | 1-gen-2008 | Galimberti, Sara; Cecconi, N; Cervetti, G; Buda, G; Orciuolo, E; Papineschi, Federico; Caracciolo, F; Benedetti, E; Petrini, Mario | |
| Chronic Myeloid Leukemia with Extreme Thrombocytocis at the Diagnosis: a New Subset | 1-gen-2016 | Sora, F.; Alessandra, I.; Latagliata, R; Castagnetti, F.; Fava, C.; Annunziata, M.; Gozzini, A.; Montefusco, E.; Avanzini, P.; Pregno, P.; Cerrano, M.; Celesti, F.; Galimberti, Sara; Bocchia, M.; Breccia, M.; Cattaneo, D.; Rosti, G; Sica, S. | |
| Circulating ringed sideroblasts in the course of the initial erythremic phase of erythroleukemia | 1-gen-1996 | Carulli, Giovanni; Fabiani, O; Azzara', Antonio |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile